ConductScience.org, home

Comparison · NCT02625974-2bb15768

Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Nifurtimox 60 Days / Arm 1 vs Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2: Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators. Trial comparisons, record NCT02625974-2bb15768. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02625974-2bb15768

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 1000.0172wilson
Risk in group 200.000000000000000003470.0335wilson
Risk difference, group 1 minus group 20-0.03350.0172newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treatfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Nifurtimox 60 Days / Arm 1Nifurtimox tablets administered three times daily for 60 days (Days 1 - 60, active nifurtimox treatment)0219OG000
Group 2Nifurtimox 30 Days, Then Placebo 30 Days / Arm 2Nifurtimox tablets administered three times daily for 30 days, followed by placebo administered three times daily for 30 days (Days 1 - 30, active nifurtimox treatment; Days 31 - 60, placebo)0111OG001

Outcome

Type
SECONDARY
Title
Part 1 - Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators
Description
Clinical significance of abnormal ECG was based on the judgement of the investigator
Time frame
Up to 420 days (Visit 11 post-treatment)
Population

Source ClinicalTrials.gov

Trial

Title
A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi
NCT number
NCT02625974
Phases
PHASE3
Conditions
Chagas Disease
Interventions
Nifurtimox (Lampit, BAYA2502), Placebo
Lead sponsor
Bayer
Results first posted
2019-10-29

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02625974-2bb15768